Medicus Pharma Ltd.

Interim MD&A - English.pdf

Interim financial statements/report – English.pdf

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Revised annual report on form 10-K - English.pdf

Annual report on form 10-K - English.pdf

Annual MD&A - English.pdf

Audited annual financial statements – English.pdf

MEDICUS PHARMA LTD CLARIFIES POSITIVE SKINJECT PHASE 2 DATASET

MEDICUS PHARMA REPORTS KOL VALIDATION OF SKINJECT PHASE 2 DATA OF 80% OVERALL RESPONSE RATE

MEDICUS PHARMA BUSINESS UPDATE CALL TO HIGHLIGHT 80% OVERALL RESPONSE RATE (ORR) IN PHASE 2 SKINJECT STUDY AND AGENTIC AI-ENABLED DRUG DEVELOPMENT PLAN

MEDICUS PHARMA REPORTS FULL-YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

MEDICUS PHARMA TO DISCUSS POSITIVE SKINJECT® PHASE 2 TOPLINE RESULTS IN FIRESIDE CHAT HOSTED BY BROOKLINE CAPITAL MARKETS

MEDICUS PHARMA ANNOUNCES SKINJECT® PHASE 2 PRINCIPAL INVESTIGATOR AND KEY OPINION LEADER (KOL), BABAR K. RAO MD, FAAD, TO PROVIDE CLINICAL INTERPRETATION OF POSITIVE DATA DURING BUSINESS UPDATE WEBCAST ON MARCH 26

MEDICUS PHARMA PROVIDES INTERPRETATION OF POSITIVE PHASE 2 SKINJECTTM DATASET

MEDICUS PHARMA REPORTS POSITIVE PHASE 2 SKNJCT-003 TOPLINE DATA OBSERVING 73% CLINICAL CLEARANCE AND 40% HISTOLOGICAL CLEARANCE (CR) AT DAY 57 IN 200µg COHORT

MEDICUS PHARMA LTD. STUDIES DEMONSTRATE LONG-ACTING THERAPEUTIC APPROACH WITH STABLE BONE TURNOVER IN WOMEN

MEDICUS PHARMA LTD. COMPLETES ENROLMENT OF NINETY (90) PATIENTS FOR PHASE 2 CLINICAL STUDY (SKNJCT-003) TO NON-INVASIVELY TREAT BASAL CELL CARCINOMA (BCC) OF THE SKIN

Interim MD&A - English.pdf

Interim financial statements/report – English.pdf

Interim MD&A - English.pdf

Interim financial statements/report – English.pdf